All News
Exciting Data for SLE: Plenaries from #ACR22
ACR Convergence 2022 promises to be another exciting year for research in systemic lupus erythematosus (SLE), with multiple plenary sessions devoted to therapeutic advancements. Here’s a quick rundown of what to expect!
Read Article
Avoid Abatacept in RA patients with a history of cancer?
The management of RA patients with a history of cancer continues to be an area of concern. General recommendations are to treat patients with a history of solid organ cancer as no different to any other RA patient. Recently, the ORAL-Surveillance study demonstrated evidence of a greater risk of cancer with tofacitinib than with TNF inhibitors. In this setting, two posters both reassure and raise a new cause for concern.
Read Article
Great start to year in review.
Beginning with JAKinibs in the much talked about ORAL Surveillance study.
Good Review of the mechanisms of action for JAKinibs
@RheumNow #ACR22 https://t.co/IF0t4uSefj
Robert B Chao, MD doctorRBC ( View Tweet)
Good grief, no! Why not get a SPECT-CT and arthroscopy on them all as well? Less is more. I will grudgingly get a plain radiograph #ACR22 https://t.co/MVx5FFRsVS
Richard Conway RichardPAConway ( View Tweet)
Abstr #0083 COVID-19 vaccine use & hesitancy among rheum pts
- 34% expressed concern for safety of primary vaccine
- 39% did not get booster due to not being told by physician
- We need to ensure pts up to date w/ vaccine including booster
https://t.co/y1vV7wbbpQ
@RheumNow #ACR22 https://t.co/gcR2yOftjq
Akhil Sood MD AkhilSoodMD ( View Tweet)
#ACR22 Abstr#0355 It can take long time for Class V #lupus nephritis (membranous) to improve. Post-hoc analysis showed in 81 pts (31 pure class V), voclosporin reduced UPCR and faster vs MMF. Stable eGFR @RheumNow #ACRBest https://t.co/gXHxEAU5tq https://t.co/o280DnTmVj
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#ACR22 Abstr#0349 We now have therapies for #lupus. How early should we use them? Real-world data showed 5-year risk of severe infection was reduced in Belimumab vs MTX/AZA/MMF initiators (adjusted to relevant confounders) @RheumNow https://t.co/xXg039zg7m https://t.co/9LEIyoakOY
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Abstr #0078
Ogdie et al found that
- Pts seen by rheumatologists more likely receive bDMARDs or csDMARDs
- Opiates & non-Opiate pain medications were more commonly prescribed to pts seen by PCPs alone
@RheumNow #ACR22
https://t.co/uDcOc0Nn3Y https://t.co/FeAq21fiVs
Akhil Sood MD AkhilSoodMD ( View Tweet)
Year in Review #ACR22
GLORIA
Low steroid usage: lower DAS28, reduced joint damage
BUT 24% increased adverse effects
@RheumNow https://t.co/vYTAhoQEqr
Eric Dein ericdeinmd ( View Tweet)
We want to see how you are taking in #ACR22! Share your favorite pictures from ACR on Twitter and tag #RheumPix and #ACR22 and we'll re-tweet our favorite ones! https://t.co/P41KybUuNw
Dr. John Cush RheumNow ( View Tweet)
Inspiring words from Dr. @cuttingforstone, "For these times, we must heed the call to adventure, find the tools & weapons never thought of before, have courage, have faith, tell our story, find our epiphanies bec this too shall pass..."
#ACR22 @RheumNow #RheumTwitter https://t.co/l3DPnIBxq6
sheila RHEUMarampa ( View Tweet)
“The Stone Age did not end because we ran out of stones, it's because we found better technology.” – Dr. A. Verghese on how we need to be smarter about the practice medicine to accomplish more without being bogged down by logistics. #scribes @cuttingforstone @rheumnow #ACR22 https://t.co/20fP8cRRrv
TheDaoIndex KDAO2011 ( View Tweet)
#ACR22 Abstr#0063 How can we improve adherence of #lupus patients to therapy? Dr Sun et al. showed reviewing prescription record in clinic and ~4min honest discussion on non-adherence improved uptake in 44% at next visit @RheumNow https://t.co/jGuK4Th1lg https://t.co/62u07jDNav
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#ACR22 Abstr#0343 Data from SLICC cohort showed non-adherence to hydroxychloroquine (detected by HCQ level) was associated with increased risk of flares, early damage and 5-yr deaths. It’s time to monitor level in patients who are not doing so well @RheumNow https://t.co/CdFIRcSYQD
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
The new IL-17A/F inhibitor, bimekizumab, was comparable to current established therapies in active #AnkylosingSpondylitis. Check our NMA poster today. #ACR22 #SpA #medtwitter @TheBold_MD @cplch19 @UTSWRheum @ACRheum @RheumNow @DrCassySims https://t.co/vxa05r0GvS
Adela Castro AdelaCastro222 ( View Tweet)
#ACR22 Abstr#0359 Is 2021 DORIS remission attainable in #lupus? Pooled analyses of Anifrolumab RCTs showed this was met in ~10% patients in treatment group vs 3% placebo. Faster and sustained too @Rheumnow https://t.co/5MY2O8i2gA https://t.co/PUeUY25JZl
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
#ACR22 Raynaud’s:
💡Primary RP is the most common
💡Autoimmune RP is rare! Other causes more common: metabolic, trauma, vibration, Buergers.
💡NMA showed that both CCB and PDE5i reduced frequency and severity of symptoms
💡Supportive measures are cornerstone!
@ACRheum @RheumNow https://t.co/tb5FEmHJDz
Adela Castro AdelaCastro222 ( View Tweet)
“For the secret of the care of the patient is in caring for the patient”
- Francis W Peabody
What a poignant end to a fantastic key note speech by Dr Abraham Verghese!
#ACR22 @RheumNow https://t.co/R6Z1h8em7n
Patricia Harkins DrTrishHarkins ( View Tweet)
"One more thing you need in a story-- Epiphany, where the soul of the commonest object seems radiant" - Dr. Verghese. His #epiphany occurred in the #HIV era helping a dying patient come to terms w/death; he discovered “The doctor can heal without curing.” #ACR22 @rheumnow https://t.co/Yh3SU4AMIZ
TheDaoIndex KDAO2011 ( View Tweet)
GCA with visual symptoms:
do you hit the pulse iv methylpred button? Why?
260 pts from Lund 🇸🇪
no doubt some channelling, but:
IVMP no better and more steroid exposure/toxicity
This adds to existing doubts. Time to seriously question this practice?
ABST0459 #ACR22 @RheumNow https://t.co/nbQlhvoRQP
David Liew drdavidliew ( View Tweet)
